



Lydia Reinhardt

Contact

Lydia Reinhardt

Publications (4)

Wagner N, Lenders M, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler T, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. *Eur J Cancer* 2023; 196:113425.

Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LG11 encephalitis. *Data Brief* 2022; 45:108649.

Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LG11 encephalitis: A retrospective multicentre cohort study. *Eur J Cancer* 2022; 175:224-235.

Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. *J Immunother Cancer* 2021; 9

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch